富瑞发布研究报告称,将神威药业评级由“持有”上调至“买入”,目标价由5.7港元升59%至14港元。该股现价低于每股6.56元的净现金价值,在过去五年派息率也超过50%,销售额于首九个月及第三季同比增22%/32%,主要是受中药颗粒业务推动,该业务还受到有利政策支持。另中药颗粒销售额同比增长56%,对总收入贡献从2017年7%增至2021年21%,今年首九个月则为27%。该行预计,集团将继续受惠于业务增长和市场份额扩大。
富瑞:上调神威药业评级至“买入” 目标价升59%至14港元
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.